Background. Adult allogeneic hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive pneumococcal disease but have suboptimal responses to the recommended pneumococcal polysaccharide vaccine (PPV23). Pneumococcal conjugate vaccine (PCV7) may improve immunogenicity in this population, and a donor vaccination strategy may benefit patients undergoing HSCT.
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at high risk of invasive pneumococcal disease. In a large European survey, the risk of invasive pneumococcal disease after allogeneic HSCT was estimated to be 8.57 cases per 1000 transplantations [1] . A retrospective review of stem cell transplant recipients from the United Kingdom estimated the risk to be 7% among allogeneic transplant recipients [2] . Similarly, a review of pneumococcal infections in HSCT recipients from a large American cancer center estimated the risk to be 7 cases per 1000 transplantations [3] . All studies found chronic graft-versus-host disease (GVHD) to be a significant risk factor for development of disease. Because of the high incidence of invasive disease, vaccination after transplantation with the pneumococcal polysaccharide vaccine (PPV23) is recommended for this population. However, both guidelines and existing clinical practices regarding timing of vaccination and the number of doses are variable, reflecting a lack of consensus regarding the optimal vaccine strategy. For example, the Centers for Disease Control and Prevention suggests vaccination with the PPV23 at 12 and 24 months after transplantation, whereas the European Bone Marrow Transplant group recommends a single dose at 12 months after transplantation [4, 5] . At our center, PPV23 is given to all allogeneic HSCT recipients at 6 and 18 months after transplantation.
Variations in vaccination practices are, in part, the result of the suboptimal immunogenicity of standard pneumococcal vaccine in this population. For example, in a study of 35 allogeneic and autologous HSCT re-cipients, PPV23 resulted in only 19% of patients developing protective titers to the 6 measured serotypes after 24 months [6] . Because of poor immunogenicity, alternative strategies for vaccination have been proposed and/or investigated. One such strategy is to vaccinate stem cell donors prior to harvesting. This would allow for adoptive transfer of immunity with transplantation. However, in a study evaluating donor vaccination with PPV23, no beneficial effect on recipient titers was observed [7] .
An alternative approach to improve immunogenicity is vaccination with the pneumococcal conjugate vaccine (PCV7). This vaccine contains 7 serotypes conjugated to a protein that allows for a T cell-dependent response to vaccination and the formation of memory B cells [8] . Although primarily evaluated in healthy pediatric populations, PCV7 has also been shown to be immunogenic in healthy adults, HIV-infected individuals, and patients who have received solid organ transplants [9] [10] [11] [12] . The vaccine contains 7 serotypes that cause 70%-80% of cases of invasive pneumococcal disease in North America [13] . In the European survey, 15 of 17 serotypes found to affect HSCT recipients were also those included in PCV7 [1] .
Because PCV7 elicits a T cell-dependent response and results in the formation of memory B cells, donor vaccination may confer adoptive transfer of immunity to the recipient. In a study of the pediatric post-HSCT population, serotype-specific response to 3 doses of PCV7 in the first year ranged from 58.1% to 93.0%, suggesting good efficacy early after transplantation [14] . In a study of HSCT recipients, donor vaccination with PCV7 appeared to enhance early antibody responses in recipients who were also given the same vaccine [15] . In this study, 3 doses of PCV7 were given early after transplantation. There has not been a direct comparison of donor and recipient paired vaccination with PPV23 with donor and recipient paired immunization with PCV7. Therefore, we conducted a randomized, double-blind, controlled trial of 2 different strategies for pneumococcal vaccination in HSCT recipients. In the first strategy, donors received PCV7 prior to harvest, and recipients received a booster dose of PCV7 at 6 months after transplantation. This was compared with a strategy of PPV23 vaccination of the donor before transplantation, followed by PPV23 vaccination of the recipient at 6 months after transplantation.
METHODS
Study design and patient population. From 2002-2005, adult patients (age, у18 years) undergoing myeloablative, matchedrelated allogeneic HSCT at the Princess Margaret Hospital (Toronto, Canada) and their donors were recruited for the study at least 2 weeks prior to stem cell harvest. Donors were randomized to receive a single 0.5 mL intramuscular dose of either PPV23 (Pneumovax; Merck) or PCV7 (Prevnar; Wyeth) at least 2 weeks before stem cell collection. A randomization schedule in blocks of 4 was created to ensure equal numbers of patients in each arm. At 6 months after transplantation, the transplant recipients received a single 0.5 mL booster dose of the same vaccine that their donor received (either PCV7 or PPV23). Serum samples were collected from recipients for determination of antibody response at baseline (the day of transplantation) and at 6 months (prior to recipient vaccination) and 12 months after transplantation. Transplants were not T cell depleted, and the mean CD34 + cell count infused was cells/kg. Clinical 6 4 ϫ 10 information, such as demographic characteristics, underlying disease, details of the transplant, the occurrence of acute and chronic GVHD, and immunosuppression, was recorded. In addition, the response in donors was determined by collecting serum samples from donors after vaccination at the time of stem cell collection. The study was approved by the institutional research ethics board and the Health Protection Branch of Health Canada. The study was registered at http://www.clin icaltrials.gov (NCT00143780).
Adverse reactions to study vaccine were determined at 24 h after vaccination in donors and recipients. The patients, their physicians, and study investigators were blinded to the vaccine type. Recipients were excluded from the trial if they had undergone a splenectomy, received pneumococcal vaccine in the 5 years prior to enrollment, or were undergoing a nonmyeloablative protocol. Recipients were followed up to 1 year after transplantation. Donors were all siblings of recipients and were excluded if they had undergone a splenectomy, received pneumococcal vaccine in the 5 years prior to enrollment, or had any medical illnesses requiring immunosuppressive medication.
Laboratory methods. Pneumococcal antibody titers were determined for each of the 7 serotypes contained in PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F) for all donors at the time of harvest (at least 2 weeks after vaccination) and for recipients at baseline and at 6 and 12 months after transplantation. Titers were determined by a serotype-specific ELISA performed at the pneumococcal reference laboratory at the University of Alabama (Birmingham, Alabama) [16] . Briefly, microtiter plates were coated with serotype-specific pneumococcal polysaccharide antigen and incubated in a humidified environment at 37ЊC. Patient serum samples were preadsorbed with cell wall polysaccharide and pneumococcal type 22F capsular polysaccharide. Serum specimens were added to the microtiter plate and incubated at room temperature. Goat anti-human IgGalkaline phosphatase conjugate was then added, followed by the addition of phosphatase substrate. A reference plasma pool (89-SF) with preassigned values was used as a control. Optical densities were then measured and converted to antibody concentrations. The lower limit of detection of this assay is ∼0.01 mg/mL. The detailed protocol can be found at http://www .vaccine.uab.edu.
Definitions. A "serotype response" was defined as a 2-fold NOTE. Data are no. (%) of recipients, unless otherwise indicated. For all comparisons, the P value was not statistically significant. GVHD, graft versus host disease; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; PCV7, 7-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; TBI, total body irradiation.
a Grade у2.
increase in titer from baseline and an absolute titer у0.35 mg/ mL. This value is used at the World Health Organization pneumococcal reference laboratory as a protective titer and is based on a pooled analysis of published clinical studies [17] . Statistical analysis. The vaccine response for each serotype was compared between the 2 groups at 6 months and 12 months after transplantation using the x 2 test or Fisher's exact test. Only recipients who had a serum sample available at at least 1 of the time points after transplantation were included in the analysis. Baseline continuous variables and antibody titers were compared between the 2 groups using the 2-tailed Student's t test for normally distributed data and using the Mann-Whitney U test for nonnormally distributed data. Logistic regression was conducted to explore available factors that might be associated with serotype response. All statistical analysis was done using SAS, version 9.0 (SAS). ). Donors were generally healthy, had no underlying con-32 ditions, and were not receiving immunosuppressive agents, such as corticosteroids. All donors were vaccinated 14-42 days before harvest. Death occurred in 20 patients (10 in the PPV23 group and 10 in the PCV7 group) prior to the 6-month followup visit, and these patients were excluded from the study analysis. Causes of death were relapse of disease ( ), sepsis n p 5 ( ), GVHD ( ), and other causes ( ). Therefore, n p 5 n p 5 n p 5 44 (68.7%) of 64 pairs were available for at least 1 follow-up visit (at 6 and/or 12 months) and were included in the analysis. The demographic characteristics and immunosuppression regimens of the 44 patients are shown in table 1.
RESULTS

Patients.
Vaccine-associated adverse reactions. Vaccine was well tolerated by the donors in both the PPV23 and PCV7 groups. Among the donors, no reaction was noted in 8 (36.4%) of 22 donors in the PPV23 group and in 9 (40.9%) of 22 donors in the PCV7 group (the P value was not statistically significant). The remainder had local tenderness (12 [54.5%] of 22 and 13 [59.1%] of 22 donors, respectively) or other relatively minor reactions. No patient had fever or other systemic reaction. Vaccine was also well tolerated by recipients in both arms of the study. Among the recipients, no reaction was noted in 7 (31.8%) of 22 recipients in the PPV23 group and in 8 (36.4%) of 22 recipients in the PCV7 group (the P value was not statistically significant). The remaining patients had mostly mild local reactions. Two patients (9.1%) in the PPV23 group had fever for 24 h.
Serotype and vaccine responses. Donor titers were measured 2-3 weeks after vaccination at the time of transplantation. Donor titers after vaccination were similar between the 2 vaccine groups (table 2), except for serotype 4, for which the titers were significantly higher in donors vaccinated with PCV7 than in those vaccinated with PPV23.
Recipient titers were evaluated at baseline (the time of transplantation) and at 6 months (prior to recipient vaccination with either PPV23 or PCV7) and 12 months after transplantation. Geometric mean titers and response rates at 6 and 12 months after transplantation are shown in table 3 and figure  1 . Response to all 7 tested serotypes (defined as an absolute titer у0.35 mg/mL and a 2-fold increase from baseline) was generally poor in both groups. However, at 6 months after transplantation, response to at least 1 serotype was seen in 8 (38.1%) of 21 patients in the PCV7 group, compared with 0 of 19 patients in the PPV23 group ( ). Because this P p .003 measurement was determined prior to any recipient vaccination, this immune response was reflective of the pretransplantation donor vaccination. The mean number of serotypes responding at 6 months after transplantation was 0 in the PPV23 group and 0.7 in the PCV7 group.
At 12 months after transplantation (6 months after recipient vaccination), response was much improved in both study arms but still tended to be better in the PCV7 group. At this time, response to at least 1 serotype was seen in 10 (55.6%) of 18 patients in the PPV23 group and in 20 (90.9%) of 22 patients in the PCV7 group ( ). When specific serotypes were P p .02 analyzed, geometric mean titers for serotypes 14 and 18C were significantly better in the PCV7 group ( and P p .034 P p , respectively) (table 3). For serotype 14, the percentage of .013 patients with response in the PCV7 group was significantly greater than the percentage of those with response in the PPV23 group (68.2% vs. 27.8%; ) (figure 1). The mean num-P p .025 ber of serotypes responding was 1.8 in the PPV23 group and 3.1 in the PCV7 group.
Univariate and multivariate logistic regression analyses were performed for the combined recipient population to determine factors associated with likelihood of vaccine response. Thirteen (32.5%) of 40 recipients had no vaccine response to any of the 7 serotypes at either 6 or 12 months after transplantation. The remaining 27 (67.5%) of 40 patients responded to у1 serotype Figure 1 . Percentage of patients responding to a vaccine serotype at 6 months (top) and 1 year (bottom) after transplantation. At 6 months after transplantation, none of the patients in the 23-valent pneumococcal polysaccharide vaccine (PPV23) group had a response to any serotype. There was no significant difference between the vaccine groups at 6 months after transplantation for any serotype. **At 12 months after transplantation, for serotype 14 in the 7-valent pneumococcal conjugate vaccine (PCV7) group, compared with the PPV23 group, . P p .025 in the vaccine. In the univariate analysis, factors shown to impact vaccine response at 6 months after transplantation were use of prednisone ( ), use of azathiaprine ( ), P p .059 P p .044 presence of chronic GVHD ( ), and vaccine type P p .035 ( ). However, in the multivariate analysis, vaccine type P p .003 was the only factor that impacted response in favor of PCV7. At 12 months after transplantation, univariate logistic regression was conducted for all of the available factors. Only vaccine type impacted response. In the multivariate analysis, the response to PCV7, compared with the response to PPV23, was associated with an odds ratio of 8.85 (95% CI, 1.62-47.6; ) after controlling for potential confounding variables, P p .012 such as transplant type (peripheral blood or bone marrow), receipt of intravenous immunoglobulin, receipt of conditioning chemotherapy, recipient age, and presence of GVHD.
Five patients (3 in the PPV23 group and 2 in the PCV7 group) received at least 1 dose of intravenous immunoglobulin early after transplantation. However, none of these patients had received this product in at least 2 months prior to titer determination; thus, it was unlikely to have affected the results. None of the patients developed microbiologically confirmed invasive pneumococcal disease during the study period.
DISCUSSION
This was, to our knowledge, the first randomized, controlled trial involving adult HSCT recipients to directly compare donor vaccination with PPV23 with donor vaccination with PCV7. At 6 months after transplantation, prior to any recipient receiving vaccination, vaccination of donors with PPV23 did not result in any significant transfer of immunity (0 serotype response). However, although still suboptimal, vaccination of donors with PCV7 resulted in at least a partial serotype response in 38.1% of recipients at 6 months after transplantation. By 12 months after transplantation (6 months after the recipient vaccination), responses were improved in both groups, although the proportion of patients with at least a 1-serotype response remained higher in the PCV7 group. Therefore, although overall responses were still suboptimal, a strategy involving vaccination of the donor and recipient with PCV7 appears to be more immunogenic than a strategy involving vaccination with PPV23.
Pneumococcal vaccine is widely recommended for and administered to allogeneic stem cell transplant recipients to prevent invasive disease (e.g., bacteremia, pneumonia, and meningitis) due to Streptococcus pneumoniae. The current guidelines of the Centers for Disease Control and Prevention recommend vaccination at 12 and 24 months after transplantation. A survey of 66 transplantation centers that was performed in 1994 revealed that 80% of programs administered pneumococcal vaccine after transplantation, although 11 different schedules were reported, and 63% gave the vaccine at р12 months after transplantation [18] . In that study, only 26% of programs reported giving у2 doses of the vaccine.
Responses to PPV23 have generally been suboptimal, and there are limited data for adults that address the timing of administration and doses of vaccine after HSCT. Standard vaccination protocols are poorly immunogenic in this patient population, compared with healthy controls [19, 20] . In a randomized trial, adult allogeneic HSCT recipients were given PPV23 either at 8 months or at 20 months after transplantation; only 10%-50% of patients had a у2-fold increase in titers for at least 1 of the 4 serotypes measured, and no difference was observed between early and late vaccination [21] . In another study, 35 HSCT recipients aged 2-45 years were vaccinated with PPV23 either once, at 24 months after transplantation, or twice, at 12 and 24 months after transplantation [7] . Only 19% of all enrolled patients developed protective titers to all 6 measured serotypes, and no significant difference between single dose and 2-dose vaccination regimens was noted. In our study, 10 (55.6%) of 18 patients in the PPV23 group responded to at least 1 serotype at 12 months after transplantation; only 2 patients (11.1%) in this group responded to 6 of the 7 serotypes. None of the patients responded to all 7 serotypes.
Studies evaluating the immunogenicity of other conjugated vaccines in HSCT recipients have shown promise. For example, Hemophilus influenzae type B conjugated vaccine was found to produce protective antibody concentrations in 55%-80% of HSCT recipients [6, 7] . The addition of donor vaccination with H. influenzae type B conjugated vaccine allowed up to 97% of HSCT recipients to respond and increased response at 3, 6, and 12 months after transplantation [7] .
One other study, by Molrine et al. [15] , has evaluated vaccination of donors with PCV7. This trial randomized donors to receive PCV7 or placebo before transplantation. The same vaccine was then given to recipients at 3, 6, and 12 months after transplantation. Among the 65 evaluable patients, geometric mean titers were significantly higher after the first 2 doses of vaccine in recipients whose donor had been immunized. However, after the third dose of vaccine, there was no difference in titers between the 2 groups, suggesting early benefit of donor immunization. Our study also revealed the benefit of donor vaccination with PCV7 early after transplantation but with continued response to PCV7 at 12 months after transplantation. The study by Molrine et al. [15] also revealed that a significantly greater number of patients whose donors had received PCV7, compared with the placebo group, responded to all 7 serotypes at 6 months after transplantation. In our study, we did not have any patient who responded to 13 serotypes at 6 months after transplantation. All patients who responded to a serotype, however, were in the PCV7 group.
Our study had several limitations. First, a higher than expected proportion of enrolled patients did not complete all of the follow-up visits, primarily because of early death. A similar rate of loss to follow-up was seen in the study by Molrine et al. [15. However, despite the small sample size, we were able to show differences between the 2 strategies. Because only these 2 specific strategies were compared, we are also not able to determine whether a strategy without any donor vaccination would have similar results. However, previous studies involving vaccination of donors with PPV23, compared with no donor immunization, have shown no benefit of donor vaccination. In addition, we did not test for serotypes absent in PCV7. It is possible that patients responded to serotypes other than those tested. We also did not universally test for hypogammaglobulinemia, which may have affected responses. Finally, we had no antibody titers available earlier than 6 months after transplantation; however, invasive pneumococcal disease generally occurs late (у100 days) after transplantation [1] .
In summary, we have shown that a strategy of donor and recipient vaccination with PCV7 improves immunogenicity at 1 year after transplantation when compared with a similar strategy with PPV23. However, overall response rates remained suboptimal with either vaccine, and further studies of modified dosing and vaccination schedules should be performed. In addition, further study is required using PCV7 as a priming vaccine, followed by a PPV23 boost; a similar strategy has been shown to increase immunogenicity in patients with Hodgkin disease [22] . Furthermore, because PCV7 includes only 7 serotypes, a strategy involving both PCV7 and PPV23 may ultimately be necessary.
